EUCTR2019-003760-47-FRActive, not recruitingPhase 1
Evaluation of 68Ga-PSMA PET-CT in the initial extension assessment of advanced renal cell carcinomaa prospective, multicenter, open study
Assistance Publique Hôpitaux de Marseille0 sites44 target enrollmentStarted: October 4, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 44
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Age = 18 years,
- •newly diagnosed patient for localized RCC intermediate or high risk (prognostic system UISS) or metastatic kidney cancer (M1 according to the TNM staging) with histological evidence (biopsy or surgical removal of part).
- •Recent conventional imaging review (from 1 month maximum on PET day at 68Ga-PSMA):
- •- cerebral CT, chest and abdominopelvic CT with iodine injection comprising an arterial and portal and late time;
- •- bone scintigraphy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 14
Exclusion Criteria
- •Pregnant or lactating woman;
- •History of other evolutionary neoplasia known in the previous 2 years
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Prospective evaluation of 68-Ga-PSMA-PET and early PSA kinetics during salvage radiotherapy for personalizing the management of men with relapse of prostate cancer after radical prostatectomy.EUCTR2015-004425-13-SESkåne University Hospital, Department of Oncology100
Active, not recruiting
Phase 1
Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management. The ProsPERo TrialMales 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on palliative systemic treatment and considered for further salvage therapyMedDRA version: 19.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10068979Term: Imaging procedureSystem Organ Class: 10022891 - InvestigationsEUCTR2016-000842-79-BEInstitut Jules Bordet75
Active, not recruiting
Phase 1
Evaluation of [68Ga]PSMA PET/MRI in intermediate and high risk prostate cancer – a comparison with mpMRI, [11C]ACE PET/CT and histopathological validatioEUCTR2015-005046-55-SEmeå University Hospital
Completed
Not Applicable
68Ga-FAPI-46 and 18F-FDG PET/CT for evaluation of head and neck squamous cell carcinoma: a comparative analysisDetection of primary cancer and metastatic lesions in patients with HNSCC.Head and Neck Neoplasms68Ga-FAPITCTR20210902003ational Cyclotron and PET Centre, Chulabhorn Hospital40
Active, not recruiting
Phase 1
Investigation of 68GaPSMA PET/CT as an imaging biomarker in solid tumorsadvanced/metastatic solid tumorsMedDRA version: 20.0Level: LLTClassification code 10027477Term: Metastatic carcinomaSystem Organ Class: 100000004864EUCTR2016-004376-21-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS400